Highlights on Future Treatments of IPF: Clues and Pitfalls
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(15), С. 8392 - 8392
Опубликована: Авг. 1, 2024
Idiopathic
pulmonary
fibrosis
(IPF)
is
an
interstitial
lung
disease
characterized
by
irreversible
scarring
of
tissue,
leading
to
death.
Despite
recent
advancements
in
understanding
its
pathophysiology,
IPF
remains
elusive,
and
therapeutic
options
are
limited
non-curative.
This
review
aims
synthesize
the
latest
research
developments,
focusing
on
molecular
mechanisms
driving
related
emerging
treatments.
Unfortunately,
several
phase
2
studies
showing
promising
preliminary
results
did
not
meet
primary
endpoints
subsequent
3,
underlying
complexity
need
for
new
integrated
endpoints.
a
challenging
condition
with
complex
interplay
genetic,
epigenetic,
pathophysiological
factors.
Ongoing
into
keystones
critical
development
targeted
therapies
that
could
potentially
stop
progression
disease.
Future
directions
include
personalized
medicine
approaches,
artificial
intelligence
integration,
growth
genetic
insights,
novel
drug
targets.
Язык: Английский
Preclinical Evaluation of the Safety, Toxicity and Efficacy of Genetically Modified Wharton’s Jelly Mesenchymal Stem/Stromal Cells Expressing the Antimicrobial Peptide SE-33
Cells,
Год журнала:
2025,
Номер
14(5), С. 341 - 341
Опубликована: Фев. 26, 2025
Mesenchymal
stem/stromal
cells
(MSCs)
offer
promising
therapeutic
potential
in
cell-based
therapies
for
various
diseases.
However,
the
safety
of
genetically
modified
MSCs
remains
poorly
understood.
This
study
aimed
to
evaluate
general
toxicity
and
Wharton's
Jelly-Derived
(WJ-MSCs)
engineered
express
antimicrobial
peptide
SE-33
an
animal
model.
Genetically
WJ-MSCs
expressing
were
administered
C57BL/6
mice
at
both
excessive
doses,
either
once
or
repeatedly.
Animal
monitoring
included
mortality,
clinical
signs,
behavioral
observations.
The
assessment
involved
histopathological,
hematological,
biochemical
analyses
major
organs
tissues,
while
immunotoxicity
immunogenicity
examined
through
humoral
cellular
immune
responses,
macrophage
phagocytic
activity,
lymphocyte
blast
transformation.
Antimicrobial
efficacy
was
evaluated
a
Staphylococcus
aureus-induced
pneumonia
model
by
mortality
assessing
bacterial
load
inflammatory
processes
lungs.
Mice
receiving
exhibited
no
acute
chronic
toxicity,
abnormalities,
pathological
changes,
regardless
dose
administration
frequency.
No
significant
alterations
responses
observed,
there
notable
changes
hematological
serum
parameters.
Infected
animals
treated
with
WJ-MSC-SE33
showed
reduction
lung
inflammation
improved
survival
compared
control
groups,
demonstrating
over
native
WJ-MSCs.
Our
findings
suggest
that
are
well
tolerated,
displaying
favorable
profile
comparable
potent
significantly
reducing
load,
inflammation,
S.
aureus
These
data
support
as
candidate
infections,
particularly
those
complicated
antibiotic
resistance.
Язык: Английский
Novel drug discovery strategies for chronic obstructive pulmonary disease: the latest developments
Expert Opinion on Drug Discovery,
Год журнала:
2025,
Номер
unknown, С. 1 - 10
Опубликована: Апрель 14, 2025
The
journey
from
initial
drug
discovery
to
approval
for
respiratory
diseases
typically
spans
approximately
10.4
years
and
cost
over
$2.8
billion.
This
intricate
process
involves
five
stages:
target
identification,
therapeutic
molecule
discovery,
preclinical
testing,
clinical
trials,
regulatory
approval.
review
examines
novel
strategies
chronic
obstructive
pulmonary
disease
(COPD),
focusing
on
advanced
in
vitro
models
that
replicate
human
lung
conditions
accurate
testing
according
the
following
search
string:
AND
strategy
COPD.
It
explores
targeted
molecular
therapies,
structure-based
design,
repurposing
approaches
facilitated
by
computational
analysis.
significance
of
personalized
medicine
tailoring
treatments
diverse
COPDs
is
emphasized,
highlighting
complexity
necessity
these
innovative
methodologies
improve
outcomes.
COPD
remains
a
challenging
area,
with
significant
unmet
medical
need.
Despite
previous
efforts,
few
effective
therapies
exist.
Innovative
models,
are
showing
promise.
Emphasizing
existing
drugs
could
transform
treatment
paradigms,
promoting
more
complex
like
These
innovations
hold
potential
enhancing
efficiency,
leading
precision
approaches.
Язык: Английский
Human Mesenchymal Stem Cell Therapy: Potential Advances for Reducing Cystic Fibrosis Infection and Organ Inflammation
Best Practice & Research Clinical Haematology,
Год журнала:
2025,
Номер
38(1), С. 101602 - 101602
Опубликована: Март 1, 2025
Язык: Английский
A review of the immunomodulatory properties of mesenchymal stem cells and their derived extracellular vesicles in small-cell and non-small-cell lung cancer cells
Radhwan Abdul Kareem,
Hayder Naji Sameer,
Ahmed Yaseen
и другие.
International Immunopharmacology,
Год журнала:
2024,
Номер
146, С. 113848 - 113848
Опубликована: Дек. 17, 2024
Язык: Английский
Adipose-Derived Mesenchymal Stem Cells (ADSCs) Have Anti-Fibrotic Effects on Lung Fibroblasts from Idiopathic Pulmonary Fibrosis (IPF) Patients
Cells,
Год журнала:
2024,
Номер
13(24), С. 2050 - 2050
Опубликована: Дек. 12, 2024
Idiopathic
pulmonary
fibrosis
(IPF)
is
the
most
common
type
of
in
lungs,
characterized
as
a
chronic
and
progressive
interstitial
lung
disease
involving
pathological
findings
with
median
survival
3
years.
Despite
knowledge
accumulated
regarding
IPF
from
basic
clinical
research,
an
effective
medical
therapy
for
condition
remains
to
be
established.
Thus,
it
necessary
further
including
stem
cell
therapy,
which
will
provide
new
insights
into
expectations
treatment.
Recently,
has
been
reported
that
one
therapeutic
candidates
adipose-derived
mesenchymal
cells
(ADSCs),
have
several
benefits,
such
easy
accessibility
minimal
morbidity
compared
bone
marrow-derived
cells.
Therefore,
we
investigated
possibility
ADSCs
candidate
IPF.
Using
human
fibroblasts
(LFs)
patients,
demonstrated
LFs
cocultured
led
reduced
fibrosis-related
genes.
Further
analysis
revealed
prevented
activation
ERK
signaling
pathway
via
upregulation
protein
tyrosine
phosphatase
receptor-type
R
(PTPRR),
negatively
regulates
pathway.
Moreover,
intravascular
administration
improved
pathogenesis
bleomycin-induced
collagen
deposition
histology
hydroxyproline
quantification
markers
gene
expression
types
I
III
α-smooth
muscle
actin
(α-SMA)
murine
model.
ADSC
transfer
was
also
humanized
mouse
model
induced
infusion
LFs,
because
bleomycin
installation
does
not
fully
recapitulate
model,
found
fibrotic
changes
lungs.
These
suggest
are
promising
Язык: Английский